149 related articles for article (PubMed ID: 24471939)
1. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
2. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of cytochrome P4A11 (CYP4A11), carbonic anhydrase 9 (CAIX) and Ki67 in renal cell carcinoma; diagnostic relevance and relations to clinicopathological parameters.
Elfakharany HK; Ghoraba HM; Gaweesh KA; Eldeen AAS; Eid AM
Pathol Res Pract; 2024 Jan; 253():155070. PubMed ID: 38183818
[TBL] [Abstract][Full Text] [Related]
5. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Courcier J; de la Taille A; Nourieh M; Leguerney I; Lassau N; Ingels A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998233
[TBL] [Abstract][Full Text] [Related]
6. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract][Full Text] [Related]
8. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
van Pel DM; Cheung S; Ionescu DN; Churg A
Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
[TBL] [Abstract][Full Text] [Related]
9. Can hypoxia marker carbonic anhydrase IX serve as a potential new diagnostic marker and therapeutic target of non-small cell lung cancer?
Fecikova S; Csaderova L; Belvoncikova P; Puzderova B; Bernatova K; Talac T; Pastorek J; Barathova M
Neoplasma; 2024 Apr; 71(2):123-142. PubMed ID: 38766851
[TBL] [Abstract][Full Text] [Related]
10. Pleural mesothelioma metastasis of the scalp.
Bicak T; Ozekinci S; İbiloğlu İ
Pol J Pathol; 2023; 74(4):297-301. PubMed ID: 38477094
[TBL] [Abstract][Full Text] [Related]
11. An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
Miller LJ; Holmes IM; Lew M
Arch Pathol Lab Med; 2024 Apr; 148(4):409-418. PubMed ID: 37622452
[TBL] [Abstract][Full Text] [Related]
12. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Brown-Glaberman U; Marron M; Chalasani P; Livingston R; Iannone M; Specht J; Stopeck AT
Dis Markers; 2016; 2016():9810383. PubMed ID: 26941473
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences of altered glycosylation of tumor-associated hypoxia biomarker carbonic anhydrase IX.
Baratova M; Skvarkova L; Bartosova M; Jelenska L; Zatovicova M; Puzderova B; Kajanova I; Csaderova L; Pastorekova S; Svastova E
Neoplasma; 2023 Jun; 70(3):416-429. PubMed ID: 37498074
[TBL] [Abstract][Full Text] [Related]
14. A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells.
Venkateswaran G; McDonald PC; Chafe SC; Brown WS; Gerbec ZJ; Awrey SJ; Parker SJ; Dedhar S
Mol Cancer Ther; 2023 Oct; 22(10):1228-1242. PubMed ID: 37348875
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats.
Okazaki Y; Chew SH; Nagai H; Yamashita Y; Ohara H; Jiang L; Akatsuka S; Takahashi T; Toyokuni S
Cancer Sci; 2020 Jun; 111(6):2016-2027. PubMed ID: 32248600
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma.
Hiraki A; Murakami T; Aoe K; Sueoka E; Sueoka N; Taguchi K; Kamei T; Sugi K; Ueoka H; Kishimoto T
Cancer Sci; 2006 Nov; 97(11):1175-81. PubMed ID: 16939492
[TBL] [Abstract][Full Text] [Related]
17. Mesothelioma: morphologic and immunohistochemical findings.
Churg A
Pathologie (Heidelb); 2024 Apr; ():. PubMed ID: 38568257
[TBL] [Abstract][Full Text] [Related]
18. Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
Szatmári T; Mundt F; Heidari-Hamedani G; Zong F; Ferolla E; Alexeyenko A; Hjerpe A; Dobra K
PLoS One; 2012; 7(10):e48091. PubMed ID: 23144729
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall.
Zhu Y; Moore S; Wang A; George E; Allard GM; Libert DM; Lowe AC
Cancer Cytopathol; 2023 Aug; 131(8):507-515. PubMed ID: 37069606
[TBL] [Abstract][Full Text] [Related]
20. Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay.
Shamis SA; Savioli F; Ammar A; Al-Badran SS; Hatthakarnkul P; Leslie H; Mallon EE; Jamieson NB; McMillan DC; Edwards J
Histol Histopathol; 2024 Feb; 39(2):177-200. PubMed ID: 37681672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
